Edition:
United Kingdom

Juniper Pharmaceuticals Inc (JNP.OQ)

JNP.OQ on NASDAQ Stock Exchange Global Select Market

11.50USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$11.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
25,124
52-wk High
$13.10
52-wk Low
$4.30

Chart for

About

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized... (more)

Overall

Beta: 0.04
Market Cap(Mil.): $50.97
Shares Outstanding(Mil.): 10.84
Dividend: --
Yield (%): --

Financials

  JNP.OQ Industry Sector
P/E (TTM): 6.24 30.93 32.76
EPS (TTM): 0.75 -- --
ROI: 20.65 15.07 14.61
ROE: 23.82 16.60 16.34

Catalent to buy Juniper Pharmaceuticals for $11.50 per share

U.S. drug contract manufacturer Catalent Inc said on Tuesday it will buy Juniper Pharmaceuticals Inc for $11.50 per share in cash.

03 Jul 2018

Catalent to buy Juniper Pharmaceuticals for $11.50 per share

July 3 U.S. drug contract manufacturer Catalent Inc said on Tuesday it will buy Juniper Pharmaceuticals Inc for $11.50 per share in cash.

03 Jul 2018

BRIEF-Juniper Pharmaceuticals Reports Q1 Earnings Per Share Of $0.06

* JUNIPER PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

10 May 2018

BRIEF-Daré Bioscience Enters Into Exclusive Worldwide License Agreement For Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform

* DARÉ BIOSCIENCE, INC. ENTERS INTO EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR JUNIPER PHARMACEUTICALS’ INTRAVAGINAL RING (IVR) TECHNOLOGY PLATFORM

25 Apr 2018

BRIEF-Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform To Daré Bioscience

* JUNIPER PHARMACEUTICALS LICENSES INTRAVAGINAL RING (IVR) PLATFORM TO DARÉ BIOSCIENCE

25 Apr 2018

BRIEF-Juniper Pharmaceuticals Appoints Richard Messina To Board Of Directors

* JUNIPER PHARMACEUTICALS APPOINTS RICHARD MESSINA TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

21 Mar 2018

BRIEF-Juniper Pharmaceuticals Qtrly Basic EPS $0.11

* JUNIPER PHARMACEUTICALS REPORTS FULL-YEAR 2017 FINANCIAL AND OPERATING RESULTS

08 Mar 2018

BRIEF-Juniper Pharmaceuticals To Explore Strategic Alternatives

* JUNIPER PHARMACEUTICALS - ‍ ENGAGED ROTHSCHILD AS ITS INDEPENDENT FINANCIAL ADVISOR TO ASSIST JUNIPER IN EVALUATING POTENTIAL STRATEGIC ALTERNATIVES​ Source text for Eikon: Further company coverage:

31 Jan 2018

Competitors

Earnings vs. Estimates